In Vivo Regulation of the Vi Antigen in Salmonella and Induction of Immune Responses with an In Vivo-Inducible Promoter

• Published in: Infection and Immunity Vol. 79; no. 6; pp. 2481 - 2488
• Main Authors: Janis, Carole, Grant, Andrew J, McKinley, Trevelyan J, Morgan, Fiona J.E, John, Victoria F, Houghton, Jenny, Kingsley, Robert A, Dougan, Gordon, Mastroeni, Pietro
• Format: Journal Article
• Language: English
• Published: Washington, DC American Society for Microbiology 01.06.2011
• Subjects: Animals; antibodies; Antibodies, Bacterial - immunology; antigens; bacteria; Bacteriology; Biological and medical sciences; Enzyme-Linked Immunosorbent Assay; Female; Fundamental and applied biological sciences. Psychology; genes; humans; immune response; immunoglobulin G; intravenous injection; liver; Liver - microbiology; Mice; Mice, Inbred BALB C; Microbial Immunity and Vaccines; Microbiology; Microscopy, Fluorescence; Miscellaneous; oral administration; pathogenicity islands; Polysaccharides, Bacterial - genetics; Polysaccharides, Bacterial - immunology; Polysaccharides, Bacterial - physiology; Promoter Regions, Genetic - immunology; Salmonella enterica subsp. enterica serovar Typhi; Salmonella typhi - genetics; Salmonella typhi - immunology; Salmonella typhi - physiology; spleen; Spleen - microbiology; typhoid fever; Typhoid Fever - immunology; Typhoid Fever - microbiology; virulence; Antigen; Salmonella; Bacteria; Immune response; Immunity; Enterobacteriaceae
• ISSN: 0019-9567; 1098-5522
• DOI: 10.1128/IAI.01265-10

Salmonella enterica serovar Typhi, the agent of typhoid fever in humans, expresses the surface Vi polysaccharide antigen that contributes to virulence. However, Vi expression can also be detrimental to some key steps of S. Typhi infectivity, for example, invasion, and Vi is the target of protective immune responses. We used a strain of S. Typhimurium carrying the whole Salmonella pathogenicity island 7 (SPI-7) to monitor in vivo Vi expression within phagocytic cells of mice at different times after systemic infection. We also tested whether it is possible to modulate Vi expression via the use of in vivo-inducible promoters and whether this would trigger anti-Vi antibodies through the use of Vi-expressing live bacteria. Our results show that Vi expression in the liver and spleen is downregulated with the progression of infection and that the Vi-negative population of bacteria becomes prevalent by day 4 postinfection. Furthermore, we showed that replacing the natural tviA promoter with the promoter of the SPI-2 gene ssaG resulted in sustained Vi expression in the tissues. Intravenous or oral infection of mice with a strain of S. Typhimurium expressing Vi under the control of the ssaG promoter triggered detectable levels of all IgG subclasses specific for Vi. Our work highlights that Vi is downregulated in vivo and provides proof of principle that it is possible to generate a live attenuated vaccine that induces Vi-specific antibodies after single oral administration.